{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:29:48Z","timestamp":1772648988798,"version":"3.50.1"},"reference-count":71,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Arkansas INBRE program and the Research Technology Core of the Arkansas INBRE program","award":["P20GM103429"],"award-info":[{"award-number":["P20GM103429"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Antimicrobial resistance (AMR) threatens global health, particularly through the rise of multidrug-resistant tuberculosis (MDR-TB) and other critical bacterial infections such as methicillin-resistant Staphylococcus aureus (MRSA). Rifamycins remain frontline antibiotics but are increasingly undermined by resistance. Here, we introduce a click-enabled platform for the synthesis of C8-functionalized rifamycins, which can be converted in a single additional step into efficacious 3\u2032-hydroxy-5\u2032-aminobenzoxazinorifamycins (bxRifs) and enzymatically into 25-deacetylated rifamycins (deAcRifs), providing access to novel antibacterial scaffolds that expand beyond the scope of traditional C8 modifications. Accordingly, we establish a modular strategy for late-stage analog development of the complex natural product rifamycin S, wherein azido and alkyne functionalities are installed via tailored core chemistry and converted into 1,2,3-triazoles through copper(I)-catalyzed click chemistry. Another key feature of this work is the development of systematic HPLC purification methods, enabling the isolation of analytically pure compounds despite structural complexity. The resulting analogs exhibit distinct antibacterial profiles, notably against Gram-positive bacteria including MRSA and Streptococcus mutans, informing structure\u2013activity relationships and offering a foundation for further optimization. This approach supports the rapid diversification of rifamycin scaffolds to combat the escalating threat of AMR, while also establishing a foundation for future discovery through bioorthogonal applications.<\/jats:p>","DOI":"10.3390\/molecules31050847","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:17:31Z","timestamp":1772641051000},"page":"847","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Late-Stage Functionalization of the Rifamycin Core via Click Chemistry Toward New Antibacterial Derivatives"],"prefix":"10.3390","volume":"31","author":[{"given":"Lola","family":"Beeser","sequence":"first","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa S.","family":"Fullerton","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Beasley","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wyatt","family":"Treadway","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Nikkel","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai Lan","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Braden","family":"Glenn","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7189-4426","authenticated-orcid":false,"given":"Catherine","family":"Mills","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailesh","family":"Budhathoki","sequence":"additional","affiliation":[{"name":"Molecular Biosciences Program, Arkansas State University, Jonesboro, AR 72401, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Parchman","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Holdiness","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Hodge","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Dragan","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-3732","authenticated-orcid":false,"given":"Mohammad Abrar","family":"Alam","sequence":"additional","affiliation":[{"name":"Molecular Biosciences Program, Arkansas State University, Jonesboro, AR 72401, USA"},{"name":"Department of Chemistry and Physics, The Beck College of Sciences and Mathematics, Arkansas State University, Jonesboro, AR 72467, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-9504","authenticated-orcid":false,"given":"Robert C.","family":"Shields","sequence":"additional","affiliation":[{"name":"Department of Oral Biology, University of Florida, Gainesville, FL 32610, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel E.","family":"Voth","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7104-3556","authenticated-orcid":false,"given":"Irosha N.","family":"Nawarathne","sequence":"additional","affiliation":[{"name":"Division of Natural Sciences, Lyon College, Batesville, AR 72501, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022, World Health Organization."},{"key":"ref_2","unstructured":"(2024, December 20). Antimicrobial Resistance. World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_3","unstructured":"(2025, January 06). CDC, Available online: http:\/\/www.cdc.gov\/tb\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/S2213-2600(24)00123-1","article-title":"New report outlines cost of inaction on AMR ahead of UN high-level meeting","volume":"12","author":"Burki","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_5","unstructured":"OECD (2018). Stemming the Superbug Tide: Just a Few Dollars More, OECD Health Policy Studies, OECD Publishing."},{"key":"ref_6","unstructured":"World Health Organization (2021). Global Tuberculosis Report 2021, World Health Organization."},{"key":"ref_7","unstructured":"World Health Organization (2023). Global Tuberculosis Report 2023, World Health Organization."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5588\/ijtld.21.0148","article-title":"The impact of COVID-19 on TB: A review of the data","volume":"25","author":"McQuaid","year":"2021","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/jmv.26311","article-title":"Association between tuberculosis and COVID-19 severity and mortality: A rapid systematic review and meta-analysis","volume":"93","author":"Gao","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_10","unstructured":"United Nations Interagency Coordination Group on Antimicrobial Resistance (2022). World TB Day 2022\u2014Online Talk Show, United Nations Interagency Coordination Group on Antimicrobial Resistance."},{"key":"ref_11","unstructured":"United Nations Interagency Coordination Group on Antimicrobial Resistance (2019). No Time to Wait: Securing the Future from Drug-Resistant Infections, United Nations Interagency Coordination Group on Antimicrobial Resistance."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Walsh, T.R., Gales, A.C., Laxminarayan, R., and Dodd, P.C. (2023). Antimicrobial Resistance: Addressing a Global Threat to Humanity. PLoS Med., 20.","DOI":"10.1371\/journal.pmed.1004264"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41594-021-00708-0","article-title":"ESKAPE velocity: Total synthesis platforms promise to increase the pace and diversity of antibiotic development","volume":"29","author":"Mattingly","year":"2022","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tube.2010.02.001","article-title":"Rifamycins\u2014Obstacles and opportunities","volume":"90","author":"Aristoff","year":"2010","journal-title":"Tuberculosis"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/ecosalplus.esp-0017-2019","article-title":"Inhibition of RNA Polymerase by Rifampicin and Rifamycin-Like Molecules","volume":"9","author":"Mosaei","year":"2020","journal-title":"EcoSal Plus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.4161\/cc.5.4.2466","article-title":"Is It Easy to Stop RNA Polymerase?","volume":"5","author":"Artsimovitch","year":"2006","journal-title":"Cell Cycle"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tube.2011.05.002","article-title":"Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases","volume":"91","author":"Gill","year":"2011","journal-title":"Tuberculosis"},{"key":"ref_18","unstructured":"(2022, March 25). Available online: https:\/\/emerypharma.com\/blog\/eskape-pathogens-explained\/."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2018.08.028","article-title":"Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis","volume":"72","author":"Mosaei","year":"2018","journal-title":"Mol. Cell"},{"key":"ref_20","unstructured":"World Health Organization (2022). Antimicrobial Resistance, World Health Organization."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8957","DOI":"10.1038\/s41598-020-65766-8","article-title":"Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species","volume":"10","author":"Ghosh","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2475067","DOI":"10.1155\/2016\/2475067","article-title":"Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens","volume":"2016","author":"Santajit","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Mulani, M.S., Kamble, E.E., Kumkar, S.N., Tawre, M.S., and Pardesi, K.R. (2019). Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.00539"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial Resistance in ESKAPE Pathogens","volume":"33","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/ja.2017.124","article-title":"Incentivising innovation in antibiotic drug discovery and development: Progress, challenges and next steps","volume":"70","author":"Simpkin","year":"2017","journal-title":"J. Antibiot."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fang, Y., Chen, X., Chu, C.H., Yu, O.Y., He, J., and Li, M. (2024). Roles of Streptococcus mutans in human health: Beyond dental caries. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1503657"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Li, X., Wang, Y., Jiang, X., Zeng, Y., Zhao, X., Washio, J., Takahashi, N., and Zhang, L. (2022). Investigation of drug resistance of caries-related streptococci to antimicrobial peptide GH12. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.991938"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1016\/j.bmcl.2011.08.054","article-title":"Synthesis and structure\u2013activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin","volume":"21","author":"Jin","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1021\/jm4004889","article-title":"X-ray Crystal Structures of the Escherichia coli RNA Polymerase in Complex with Benzoxazinorifamycins","volume":"56","author":"Molodtsov","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/jm201716n","article-title":"Structure-Based Design of Novel Benzoxazinorifamycins with Potent Binding Affinity to Wild-Type and Rifampin-Resistant Mutant Mycobacterium tuberculosis RNA Polymerases","volume":"55","author":"Gill","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1128\/AAC.35.3.542","article-title":"In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins","volume":"35","author":"Saito","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.2174\/1381612043383287","article-title":"In Vitro and In Vivo Activities of New Rifamycin Derivatives Against Mycobacterial Infections","volume":"10","author":"Lounis","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/AAC.39.2.440","article-title":"In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli","volume":"39","author":"Reddy","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1128\/AAC.40.2.426","article-title":"In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis","volume":"40","author":"Yamamoto","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/mmi.13606","article-title":"Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis","volume":"103","author":"Molodtsov","year":"2017","journal-title":"Mol. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: Rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yang, L., Liao, Z.-Z., Ran, L., and Xiao, X.-H. (2025). Progress of arylacetamide deacetylase research in metabolic diseases. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1564419"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/23744235.2024.2309348","article-title":"Variability in plasma rifampicin concentrations and role of SLCO1B1, ABCB1, AADAC2 and CES2 genotypes in Ethiopian patients with tuberculosis","volume":"56","author":"Sileshi","year":"2024","journal-title":"Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click Chemistry: Diverse Chemical Function from a Few Good Reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1359-6446(03)02933-7","article-title":"The growing impact of click chemistry on drug discovery","volume":"8","author":"Kolb","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1016\/j.tet.2016.07.044","article-title":"Advances of Azide-Alkyne Cycloaddition-Click Chemistry over the Recent Decade","volume":"72","author":"Singh","year":"2016","journal-title":"Tetrahedron"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1039\/B613014N","article-title":"The growing applications of click chemistry","volume":"36","author":"Moses","year":"2007","journal-title":"Chem. Soc. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccr.2016.02.010","article-title":"Metal-catalyzed azide-alkyne \u201cclick\u201d reactions: Mechanistic overview and recent trends","volume":"316","author":"Wang","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","article-title":"A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective \u201cLigation\u201d of Azides and Terminal Alkynes","volume":"41","author":"Rostovtsev","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1021\/acs.chemrev.1c00469","article-title":"Introduction: Click Chemistry","volume":"121","author":"Devaraj","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/med.20107","article-title":"Click chemistry reactions in medicinal chemistry: Applications of the 1,3-dipolar cycloaddition between azides and alkynes","volume":"28","author":"Tron","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0040-4039(00)61868-3","article-title":"A facile synthesis of functionalized 9,10- anthracenediones via tosylate and triflate phenolic activation","volume":"26","author":"Showalter","year":"1985","journal-title":"Tetrahedron Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/ar200148z","article-title":"From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions","volume":"44","author":"Sletten","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1021\/acs.bioconjchem.1c00461","article-title":"Bioorthogonal Chemistry and Its Applications","volume":"32","author":"Bird","year":"2021","journal-title":"Bioconjugate Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC Technology: Opportunities and Challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0021-9673(01)89658-8","article-title":"Identification and quantitation of rifamycins by reversed-phase high-performance liquid chromatography","volume":"477","author":"Vohra","year":"1989","journal-title":"J. Chromatogr. A"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11094-019-02041-9","article-title":"Stability-Indicating HPLC Determination of Rifampicin in Bulk Drug and Dosage Form","volume":"53","author":"Swamy","year":"2019","journal-title":"Pharm. Chem. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40995-023-01471-1","article-title":"Swift and Precise Determination of Rifampicin by RP-HPLC Technology Development in Pharmaceuticals","volume":"47","author":"Aqil","year":"2023","journal-title":"Iran. J. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1046\/j.1365-2672.2000.01017.x","article-title":"Susceptibility testing: Accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values","volume":"88","author":"Lambert","year":"2000","journal-title":"J. Appl. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/cix1127","article-title":"Busting the Myth of \u201cStatic vs Cidal\u201d: A Systemic Literature Review","volume":"66","author":"Holtom","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkae380","article-title":"Bactericidal versus bacteriostatic antibacterials: Clinical significance, differences and synergistic potential in clinical practice","volume":"80","author":"Ishak","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zmerli, O., Hodzic, A., Bellali, S., Azar, E., and Bou Khalil, J. (2024). Early prediction of the bactericidal and bacteriostatic effect of imipenem and doxycycline using tabletop scanning electron microscopy. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1431141"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kuznetsova, M.V., Nesterova, L.Y., Mihailovskaya, V.S., Selivanova, P.A., Kochergina, D.A., Karipova, M.O., Valtsifer, I.V., Averkina, A.S., and Star\u010di\u010d Erjavec, M. (2025). Nosocomial Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus: Sensitivity to Chlorhexidine-Based Biocides and Prevalence of Efflux Pump Genes. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010355"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1021\/acsami.4c20278","article-title":"A Conjugated Oligomer with Drug Efflux Pump Inhibition and Photodynamic Therapy for Synergistically Combating Resistant Bacteria","volume":"17","author":"Li","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"156319","DOI":"10.1016\/j.phymed.2024.156319","article-title":"Curcumin reverses high-level tigecycline resistance mediated by different mechanisms in Gram-negative bacteria","volume":"136","author":"Zheng","year":"2025","journal-title":"Phytomedicine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/CMR.00117-14","article-title":"The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria","volume":"28","author":"Li","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e00452-24","DOI":"10.1128\/aac.00452-24","article-title":"The intrinsic macrolide resistome of Escherichia coli","volume":"68","author":"Ma","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1574-6976.2011.00290.x","article-title":"Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria","volume":"36","author":"Nikaido","year":"2012","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Compagne, N., Vieira Da Cruz, A., M\u00fcller, R.T., Hartkoorn, R.C., Flipo, M., and Pos, K.M. (2023). Update on the Discovery of Efflux Pump Inhibitors against Critical Priority Gram-Negative Bacteria. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010180"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s00203-023-03539-3","article-title":"The Role of Efflux Pumps in Antibiotic Resistance of Gram Negative Rods","volume":"205","year":"2023","journal-title":"Arch. Microbiol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Alenazy, R. (2022). Drug Efflux Pump Inhibitors: A Promising Approach to Counter Multidrug Resistance in Gram-Negative Pathogens by Targeting AcrB Protein from AcrAB-TolC Multidrug Efflux Pump from Escherichia coli. Biology, 11.","DOI":"10.3390\/biology11091328"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Itzia Azucena, R.C., Jos\u00e9 Roberto, C.L., Martin, Z.R., Rafael, C.Z., Leonardo, H.H., Gabriela, T.P., and Araceli, C.R. (2019). Drug Susceptibility Testing and Synergistic Antibacterial Activity of Curcumin with Antibiotics against Enterotoxigenic Escherichia coli. Antibiotics, 8.","DOI":"10.3390\/antibiotics8020043"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1021\/acs.joc.3c02646","article-title":"Domino Reaction Protocol to Synthesize Benzothiophene-Derived Chemical Entities as Potential Therapeutic Agents","volume":"89","author":"Roy","year":"2024","journal-title":"J. Org. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13622","DOI":"10.1021\/acs.jmedchem.3c00969","article-title":"Development and Antibacterial Properties of 4-[4-(Anilinomethyl)-3-phenylpyrazol-1-yl]benzoic Acid Derivatives as Fatty Acid Biosynthesis Inhibitors","volume":"66","author":"Roy","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e202402485","DOI":"10.1002\/slct.202402485","article-title":"Synthesis of Thiazole-Fused Diosgenin Derivatives as Potential Therapeutic Agents","volume":"9","author":"Roy","year":"2024","journal-title":"ChemistrySelect"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"101300","DOI":"10.1016\/j.mex.2021.101300","article-title":"Generating single-stranded DNA circles with minimal resources","volume":"8","author":"Ford","year":"2021","journal-title":"MethodsX"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/5\/847\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:22:22Z","timestamp":1772641342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/5\/847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["molecules31050847"],"URL":"https:\/\/doi.org\/10.3390\/molecules31050847","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}